Photo by ang10ze from unsplash
The benefit from adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC) is modest with an overall survival (OS) benefit of only ~5% demonstrated in the Lung Adjuvant Cisplatin Evaluation… Click to show full abstract
The benefit from adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC) is modest with an overall survival (OS) benefit of only ~5% demonstrated in the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis (1).
Keywords:
bootstraps hunt;
nsclc;
hunt prognostic;
prognostic predictive;
laces bootstraps;
predictive markers
Journal Title: Translational lung cancer research
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Translational lung cancer research
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!